Joseph Ciaffoni
Known title: President and CEOCIK: 0001443841
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
Transaction History
| INDV | ▲ Buy | Option Exercise | 1,266,903 | — | 6/22/2026 | View on chart |
| INDV | ▼ Sell | Tax Withholding | 612,549 | $23.5M | 6/22/2026 | View on chart |
| INDV | ▲ Buy | Grant | 79,976 | $0 | 2/10/2026 | View on chart |
| COLL | ▲ Buy | Grant | 119,000 | $0 | 2/12/2024 | View on chart |
| COLL | ▲ Buy | Grant | 179,734 | $0 | 2/12/2024 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 47,445 | $1.6M | 2/12/2024 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 81,422 | $2.7M | 2/12/2024 | View on chart |
| COLL | ▲ Buy | Option Exercise | 4,357 | $93K | 12/21/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 4,357 | $132K | 12/21/2023 | View on chart |
| COLL | ▲ Buy | Option Exercise | 26,454 | $565K | 12/20/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 26,454 | $804K | 12/20/2023 | View on chart |
| COLL | ▲ Buy | Option Exercise | 14,516 | $310K | 12/19/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 14,516 | $436K | 12/19/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 27,798 | $835K | 12/18/2023 | View on chart |
| COLL | ▲ Buy | Option Exercise | 27,798 | $593K | 12/18/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 30,272 | $653K | 6/2/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 1,000 | $22K | 6/2/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 31,272 | $691K | 6/1/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 31,272 | $684K | 5/31/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 31,271 | $685K | 5/30/2023 | View on chart |
| COLL | ▲ Buy | Option Exercise | 11,250 | $179K | 2/13/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 11,250 | $302K | 2/13/2023 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 59,736 | $1.6M | 2/10/2023 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 44,121 | $1.2M | 2/10/2023 | View on chart |
| COLL | ▲ Buy | Grant | 117,500 | $0 | 2/10/2023 | View on chart |
| COLL | ▲ Buy | Grant | 137,694 | — | 2/10/2023 | View on chart |
| COLL | ▼ Sell | Open Market | 1,804 | $43K | 12/27/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 400 | $10K | 12/27/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 147 | $3K | 12/23/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 110 | $3K | 12/22/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 7,333 | $169K | 12/21/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 9,375 | $216K | 12/20/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 1,134 | $26K | 12/19/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 54,400 | $1.3M | 12/2/2022 | View on chart |
| COLL | ▲ Buy | Option Exercise | 76,653 | $1.2M | 12/1/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 76,653 | $1.7M | 12/1/2022 | View on chart |
| COLL | ▲ Buy | Option Exercise | 43 | $684 | 11/28/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 43 | $946 | 11/28/2022 | View on chart |
| COLL | ▲ Buy | Option Exercise | 65 | $1K | 11/22/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 65 | $1K | 11/22/2022 | View on chart |
| COLL | ▲ Buy | Option Exercise | 1,989 | $32K | 11/18/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 1,989 | $44K | 11/18/2022 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 1,394 | $25K | 7/1/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 65,083 | $1.2M | 3/1/2022 | View on chart |
| COLL | ▼ Sell | Open Market | 11,011 | $210K | 3/1/2022 | View on chart |
| COLL | ▲ Buy | Grant | 125,000 | $0 | 2/10/2022 | View on chart |
| COLL | ▲ Buy | Grant | 65,034 | — | 2/10/2022 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 24,154 | $426K | 2/10/2022 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 28,843 | $509K | 2/10/2022 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 1,090 | $20K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Indivior reports Sublocade sales growth and higher profitability
Indivior disclosed that sales of its Sublocade treatment are expanding, contributing to better overall profitability. The improvement in earnings aligns with the company's trailing P/E of 11.8 and analyst price targets that average $49. The news may influence how investors view the stock's valuation relative to its recent support level.
Indivior reports Sublocade sales growth and higher profitability. Indivior disclosed that sales of its Sublocade treatment are expanding, contributing to better overall profitability. The improvement in earnings aligns with the company's trailing P/E of 11.8 and analyst price targets that average $49. The news may influence how investors view the stock's valuation relative to its recent support level.